HUTCHMED is a global biopharmaceutical company that discovers, develops, and commercializes targeted therapies and immunotherapies for cancer and immunological diseases, with a primary focus on oncology. The company generates revenue from three main sources: direct sales of internally developed drugs in China (including VEGFR, MET, and other targeted inhibitors), royalties and milestone payments from global partnerships with major pharmaceutical companies like AstraZeneca and Eli Lilly, and drug distribution and marketing services through its Other Ventures operations in China. Operating from research and manufacturing facilities in China with commercial sales teams throughout the country, HUTCHMED leverages China's large patient population and favorable regulatory environment while expanding internationally through established partnerships to bring its differentiated small-molecule inhibitor and antibody-based therapeutics to global markets.